期刊文献+

^(18)F-FLT PET/CT显像在恶性肿瘤诊断中的应用价值 被引量:4

Application value of ^(18)F-FLT PET/CT fusion imaging in the different carcinomas
原文传递
导出
摘要 目的探讨3′-脱氧-3′-18F-氟代胸苷(18F-FLT)PET/CT显像在恶性肿瘤诊断中的应用价值。方法对31例恶性肿瘤患者行18F-FLT PET/CT显像,分析18F-FLT PET/CT显像中病灶感兴趣区(ROI)最大标准摄取值(SUVmax)和平均标准摄取值(SUVmean)与肿瘤类型、病理类型和分期的关系。结果 18F-FLT PET/CT显像图像质量好,病灶显影清晰。31例共发现100处病灶18F-FLT高摄取,SUVmax为(5.20±2.79),SUVmean为(4.35±2.38);其中,肺癌患者淋巴结转移4处,SUVmax为(2.29±1.54),SUVmean为(1.72±1.09),较鼻咽癌组低(P<0.05);鼻咽癌不同病理类型间SUV值差异无统计学意义(P>0.05)。结论 18F-FLT PET/CT显像能清晰显示鼻咽癌、肺癌、淋巴瘤、喉癌、肾盂癌原发病灶及转移病灶,有临床应用价值。 Objective to evaluate the usefulness of 18F-FLT PET/CT fusion imaging in different carcinomas.Methods Thirty-one patients with histologically proven carcinoma underwent whole-body 18F-FLT PET/CT scan.The maximum standard uptake value(SUVmax) and nean SUV(SUVmean) for 18F-FLT were calculated.Results In all patients,18F-FLT uptake could be detected in the primary tumor or metastasis site.The SUVmax and SUVmean for 18F-FLT in 100 lesions of 31 patients with carcinoma were (5.20±2.79) and(4.35±2.38),respectively.The SUVmax and SUVmean of metastasis lesions of lung cancer were(2.29±1.54) and(1.72±1.09),which were lower than those of nasopharyngeal carcinoma lesions(P0.05).Conclusion 18F-FLT PET/CT imaging provides an useful supplementary information that assists the diagnosis of carcinomas.
出处 《江苏医药》 CAS CSCD 北大核心 2011年第9期1056-1058,共3页 Jiangsu Medical Journal
基金 苏州市社会发展计划项目(SS08031SS0807)
关键词 18F-FLT PET/CT 恶性肿瘤 18F-FLT PET/CT Carcinoma
  • 相关文献

参考文献9

  • 1Chen W,Cloughesy T,Kamdar N,et al. Imaging proliferation in brain tumors with ^18F-FLT PET: comparison with ^18F-FDG [J]. J Nucl Med,2005,46(6):945-952.
  • 2谭业颖.^18F-氟脱氧胸苷PET的肿瘤分子显像研究进展[J].国际放射医学核医学杂志,2007,31(1):6-8. 被引量:1
  • 3Buck AK,Schirrmeister H, Hetzel M, et al. 3-Deoxy-3-[^18F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules[J].Cancer Res, 2002,62(12) : 3331-3334.
  • 4Yamamoto Y, Nishiyama Y, Kimura N, et al. Comparison of ^18F-FLT PET and ^18F FDG PET for preoperative staging in non-small cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2008,35 (2) : 236 245.
  • 5Dittmann H,Dohmen BM, Paulsen F, et al. ^18 F-FLT PET for diagnosis and staging of thoracic tumors[J]. Eur J Nucl Med Mol Imaging, 2003,30(10) : 1407-1412.
  • 6关晏星.乳腺癌核素分子显像的临床研究进展[J].国际放射医学核医学杂志,2006,30(4):225-228. 被引量:2
  • 7Francis DL, Visvikis D, Costa IX;, et al. Potential impact of [^18F]3'-deoxy- 3'-fluorothymidine versus [^18F]fluoro-2 deoxy- D-glucose in positron emission tomography for colorectal cancer[J]. Eur J Nucl Med Mol Imaging, 2003, 30 (7) : 988- 994.
  • 8Herrmann K,Wieder HA, Buck AK,et al. Early response assessment using 3r-deoxy-3' [^18F] {luorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma [J]. Clin Cancer Res,2007,13(12) ..3552-3558.
  • 9Lu L,Samuelesson L,Bergstrom M, et al. Rat studies compa ring ^11C-FMAU ^18FFLT, and ^76Br-BrFU as proliferation markers[J]. J Nucl Med,2002,43(12):1688-1698.

二级参考文献50

  • 1王玲,张炽敏.乳腺肿瘤的影像学诊断进展[J].国外医学(放射医学核医学分册),2005,29(2):93-96. 被引量:17
  • 2Buck AK,Schirmeister H,Mattfeldt T,et al.Biological characterization of breast cancer by means of PET.Eur J Nucl Med Mol Imaging,2004,31(Suppl 1):S80-S87.
  • 3Wu D,Gambhir SS.Positron emission tomography in diagnosis and management of invasive breast cancer:.Current status and future perspectives.Clin Breast Cancer,2003,4 (Suppl 1):S55-S63.
  • 4Kumar A.Fluorodeoxyglucose-PET in the management of breast cancer.Radiol Clin North Am,2004,42(6):1113-1122.
  • 5Andrew Q,Sanjiv S G.FDG-PET and beyond:Molecular breast cancer imaging.J Clin Oncol,2005,23(8):1664-1673.
  • 6Wang Y,Yu J,Liu J,et al.PET-CT in the diagnosis of both primary breast cancer and axillary lymph node metastasis:initial experience.Int J Radiat Oncol Biol Phys,2003,57 (Suppl 1):362-363.
  • 7Bellon JR,Livingston RB,Eubank WIB.Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer(LABC).Am J Clin Oncol,2004,27(4):407-410.
  • 8Eubank WB,Mankoff DA,Takasugi J,et al.18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer.J Clin Oncol,2001,19(12):3516-3523.
  • 9Lin WY,Tsai SC,Cheng KY,et al.Fluroine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancerTaiwan Residents experiences.Cancer Invest,2002,20(5-6):725-729.
  • 10Pecking Ap,Mechelany-Corone C,Bertrand-kermorgant F,et al.Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomogaphy.Clin Breast Cancer,2001,2(3):229-234.

共引文献1

同被引文献44

  • 1柳曦,周乃康,张锦明,梁朝阳,张竞,郑昕.^(18)F-FLT在小鼠肺癌和炎症模型中的生物分布及PET显像研究[J].第三军医大学学报,2007,29(9):798-800. 被引量:6
  • 2YAMAMOTO Y,NISHIYAMA Y,KIMURA N,et al.Comparison of 18F-FLT PET and 18F-FDG PET for preoperative staging in non-small cell lung cancer[J].Eur J Nucl Med Mol Imaging,2008,35(2):236-245.
  • 3Chan SC, Chang JT, Wang HM et al. Prediction for distant failure in patients with stage Mo nasopharyngeal carcinoma: the role of standardized uptake value[J]. Oral Oncol, 2009,45 ( 1 ): 52-8.
  • 4Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for medi astinal staging in patients with non-small-cell lung cancer:a meta-analysis[J]. Ann Intern Med,2003,139( 11 ):879-92.
  • 5Hong IK,Kim JH,Ra YS,et al. Diagnostic usefulness of 3'-deoxy-3r-[(18)F]fluorothymidine positron emission tomography in recurrent brain tumor [J]. J Comput Assist Tomogr,2011, 35(6) :679-84.
  • 6van Waarde A, Cobben DC, Suumeijer AJ, et al. Selectivity of ^18F- FLT and ^18F-FDG for differentiating tumor from inflammation in a rodent model[J]. J Nucl Med, 2004,45 (4) : 695-700.
  • 7Yamamoto Y,Nishiyama Y,Ishikawa S,et al. 3' Deoxy 3' ^18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fIuoro D-glucose[J]. J Compute Assist Tomogr,2008,32(3):432-7.
  • 8Yen TC, Chang YC, Chan SC, et al. Are dual-phase ^18F-FDG PET scans necessary in nasopharygeal carcinoma to assess the pri mary tumour and loco-regional nodes? [J]. Eur J Nucl Med Mol Imaging, 2005,32 (5): 541-8.
  • 9Shim SS, Lee KS, Kim BT, et al. Non small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging[J]. Radiology, 2005,236 (3) : 1011-9.
  • 10Pauls S, Buck AK, Hohl K, et al. Improved non-invasive T-Staging in non small cell lung cancer by integrated ^18F-FDG PET/CT [J]. Nuklcarmedizin, 2007,46 ( 1 ) : 9-14.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部